Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

PURPOSE: Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed/refractory cHL after autologous hematopoietic cell transplantation (auto-HCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Shipp, Margaret A., Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto, Ansell, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075855/
https://www.ncbi.nlm.nih.gov/pubmed/29584546
http://dx.doi.org/10.1200/JCO.2017.76.0793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075855/
https://www.ncbi.nlm.nih.gov/pubmed/29584546
http://dx.doi.org/10.1200/JCO.2017.76.0793

Ejemplares similares